Featured Bioprocessing Editorial

  1. How To Grow CHO Cells Without Cysteine, Tyrosine Feeds 9/19/2025

    Researchers at Pfizer are developing a cell line that synthesizes these amino acids autonomously, which could reduce costs and increase stability.

  2. Making The Leap To Smart Bioprocessing 9/19/2025

    A European consortium achieved greater T cell expansion compared to baseline conditions using real-time process monitoring and control.

  3. Unlocking Method Insights For Novel Engineered AAV Capsids 9/18/2025

    Microfluidic platforms, such as labchip, are widely used for assessing wild type capsids. Now, engineered capsids are challenging these established workflows.

  4. Why FDA's Tough Talk On Foreign Inspections Is More Bark, Less Bite 9/18/2025

    FDA Commissioner Marty Makary has promised to end the so-called "double standard" of announced overseas inspections. Does the agency have the resources?

  5. Manufacturing Interleukin-2 For In Vivo Use: Key Considerations 9/16/2025

    Interleukins help optimize therapeutic outcomes in cancer immunotherapy and regenerative medicine. Manufacturing success requires stringent control over production, formulation, and stability to ensure safety and efficacy.

  6. Sanofi's Digitalization Road Trip Shifts Into High Gear 9/16/2025

    The company's head of manufacturing discusses their latest investments in AI and automation, plus offers tips on how any company can start adopting advanced technology.

  7. Why Pharmaceutical And Medical Device Risks Must Be Analyzed By Their Risk Mechanisms 9/16/2025

    Current risk analysis methods focus on the possibility and severity of bad events instead of focusing directly on analyzing and improving the performance of systems and processes producing the bad events. 

  8. NanoCell's Moonshot Aims To Unlock In Vivo Cell Therapy 9/16/2025

    If the science holds, the implications include substantial cost reduction and putting engineered T cell therapies within reach of patients anywhere in the world.

  9. The Regulatory Imperative To Improve Environmental And Sustainability Stewardship In Biopharma 9/15/2025

    As the industry faces increasing pressure to align with environmental, social, and governance (ESG) standards, companies must evaluate how to integrate supply chain management with these initiatives to drive sustainability and mitigate risks.

  10. How You And Your CDMO Should Leverage Contamination Control Strategies For Competitive Advantage 9/15/2025

    It is no longer sufficient to just meet compliance requirements; a proactive, risk-based approach to contamination control is now a differentiating factor that enhances operational efficiency and more. For biotech companies evaluating CDMOs, this shift is critical.